Visceral Kaposiʼs Sarcoma Remission After Intestinal Transplant. First Case Report and Systematic Literature Review (original) (raw)
Related papers
Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study
Journal of the American Academy of Dermatology, 2019
Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors and/or chemotherapy. Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months. Results: Ninety five percent, 28% and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. Overall, 83% of patients had response at 6 months including 40% complete responses (CR). Limitations: The retrospective design of the study. Conclusion: Currently available therapeutic options seem to be effective to control KS in a majority of patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.
Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus
Experimental and Clinical Transplantation, 2005
The prevalence of Kaposi's sarcoma (KS) is much greater in organ transplant recipients than it is in the general population. Its etiology appears to be related to geographic, genetic, and viral factors. Treatment of transplant-related KS has, until now, consisted mainly of reduction of, or withholding of, immunosuppression, often with deleterious effects on both graft and patient survival. In recent years, the immunosuppressive drug, sirolimus, has been demonstrated as possessing anti-neoplastic properties in both in vitro and animal models. In view of these properties and some preliminary clinical experience, we postulated that sirolimus would be beneficial in our patients who developed transplant-related KS. Here, we report the first case of a patient with both cutaneous and visceral KS who was successfully treated in the Middle East by conversion from a cyclosporine-based to a sirolimus-based immunosuppression regimen. The KS regressed completely within a few months after the...
Clinicopathological Aspects of 18 Kaposi's Sarcoma among 1055 Greek Renal Transplant Recipients
Artificial Organs, 2004
Fulminant myocarditis causes substantial morbidity and mortality, especially in children and young adults. Mechanical circulatory support has become the standard therapy to bridge patients with intractable heart failure to either transplantation or myocardial recovery. Yet, successful weaning from biventricular support with full recovery is extremely rare in the pediatric population. This report describes the successful use of the MEDOS HIA ventricular assist device to bridge a 12-year-old girl to myocardial recovery in a biventricular bypass configuration. The left and right ventricle were completely offloaded by the pumps and the device provided sufficient cardiac output to normalize end-organ function. Anticoagulation was maintained with i.v. heparin infusion. No neurological complications were detectable and the pump system was free of any macroscopic thrombi. After 19 days of support, cardiac function had recovered and the patient was successfully weaned from the device. Following physical rehabilitation, the patient was discharged home.
Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppressiony
Background. The aim of this study was to investigate retrospectively the clinical presentation, the efficacy of reducing immunosuppression and the consequences of this therapeutic approach in Kaposi's sarcoma (KS) developing after renal transplantation. Methods. We reviewed the records of 502 patients who had been followed up at our transplantation unit between October 1, 1987 and December 30, 1998. Twelve patients (2.4%) with KS were included in the study.
Sarcoma de Kaposi pós-transplante hepático: relato de caso
Revista de Medicina, 2022
Introduction: Kaposi's Sarcoma is a multicentric malignant neoplasm characterized by the development of purple tumors, which can be seen on the skin and subcutaneous tissue and on viscera. The objective of this study was to report a case of Kaposi's Sarcoma after liver transplantation, considering the rarity of this event. Method: The research instrument used to conduct this report was the case study, with collection of information from the patient's physical record. Case report: A 28-year-old man with a history of using Tacrolimus for three years due to liver transplantation, presented abdominal pain associated with diarrhea, and was diagnosed with Kaposi's Sarcomi through histopathological examination of intestinal polyp and referred for chemotherapy treatment. Final considerations: Patients who were submitted to solid organ transplants and treated with immunodepressive medications should have any new symptoms carefully investigated to allow an early diagnosis of neoplasia.
2022
Introduction: Kaposi's Sarcoma is a multicentric malignant neoplasm characterized by the development of purple tumors, which can be seen on the skin and subcutaneous tissue and on viscera. The objective of this study was to report a case of Kaposi's Sarcoma after liver transplantation, considering the rarity of this event. Method: The research instrument used to conduct this report was the case study, with collection of information from the patient's physical record. Case report: A 28-year-old man with a history of using Tacrolimus for three years due to liver transplantation, presented abdominal pain associated with diarrhea, and was diagnosed with Kaposi's Sarcomi through histopathological examination of intestinal polyp and referred for chemotherapy treatment. Final considerations: Patients who were submitted to solid organ transplants and treated with immunodepressive medications should have any new symptoms carefully investigated to allow an early diagnosis of neoplasia.
Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient
Clinical and Experimental Nephrology, 2007
The incidence of Kaposi's sarcoma among recipients of solid organs is about 500 times the rate in the general population, suggesting a role for immunosuppression in its development. On the basis of these findings, we investigated the impact of sirolimus on cutaneous and disseminated visceral Kaposi's sarcoma in a renal-transplant recipient. The introduction of sirolimus in this patient allowed complete regression of Kaposi's sarcoma (cutaneous and visceral) with preservation of excellent renal function. Meanwhile, in view of the available observational reports, we think that sirolimus should be included in the standard treatment for Kaposi's sarcoma after transplantation, to permit remission of the sarcoma (both cutaneous and visceral) while preserving the renal function.